Clinical trials: Liraglutide
Diabetes, Healthy
Safety and Tolerability of Liraglutide in Healthy Male Volunteers
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after five ascending single doses of NNC 90-1170 (liraglutide).
- Trial name
- NCT01507272
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with…
- Trial name
- NCT01617434
- Testing
- liraglutide
- Where
- 86 sites in United States, Argentina and 7 more
- Volunteers
- 451 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes (T2DM).
- Trial name
- LIRA-LIXI™ (NCT01973231)
- Testing
- liraglutide, lixisenatide
- Where
- 61 sites in Czechia, Finland and 7 more
- Volunteers
- 404 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral…
- Trial name
- DUAL™ I China (NCT03172494)
- Testing
- Insulin degludec/liraglutide, Insulin degludec, Liraglutide
- Where
- 36 sites in China
- Volunteers
- 720 people
- Sponsor
- Novo Nordisk A/S
Nonalcoholic Steatohepatitis
Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
The purpose of this study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight…
- Trial name
- LEAN (NCT01237119)
- Testing
- Liraglutide
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- University of Birmingham
Diabetes Complications, Osteoporosis
The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function.
- Trial name
- LIRABONE (NCT02473809)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Type 2 Diabetes
GLP-1 and Microvascular Function in Type 2 Diabetes
Some gut hormones, called incretins, stimulate insulin production in order to control sugar levels but also activate brain centres and signal to stop eating.
- Trial name
- GLP-1ADDS (NCT01740921)
- Testing
- Liraglutide, diet, Aspirin
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Type 2 Diabetes Mellitus
GLP-1/Basal Insulin Combination Therapy
This is a real-world, pre-post observational study from an ambulatory endocrinology practice which will determine the effectiveness and safety of the addition of glucagon-like peptide-1(GLP-1) agonist therapy (weekly exenatide…
- Trial name
- NCT02895672
- Testing
- GLP-1 therapy
- Volunteers
- 150 people
- Sponsor
- Albany College of Pharmacy and Health Sciences
Polycystic Ovary
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with PCOs.
- Trial name
- NCT05965908
- Testing
- liraglutide, Metformin
- Where
- Egypt
- Volunteers
- 183 people
- Sponsor
- Beni-Suef University
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
T2DM (Type 2 Diabetes Mellitus), Fatty Liver
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, liraglutide, or…
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Fatty Liver, NAFLD
- Trial name
- ALT (NCT03233178)
- Testing
- Non-interventional
- Where
- Canada
- Volunteers
- 4,000 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Coronary Artery Disease, Diabetes Mellitus, Type 2
The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes
The purpose of this study is to investigate the effect of combined glucagon-like-peptide-1 (GLP-1) analogue and metformin therapy on glucose metabolic and cardiovascular endpoints compared to metformin monotherapy in patients…
- Trial name
- AddHope2 (NCT01595789)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 41 people
- Sponsor
- Haugaard, Steen Bendix, M.D., DMSc
Type 1 Diabetes
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2.
- Trial name
- 1974 (NCT02777073)
- Testing
- Victoza, Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University at Buffalo
Type 2 Diabetes Mellitus, End-stage Renal Disease
Liraglutide Treatment to Patients With Severe Renal Insufficiency
Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is new and fundamentally different from the classical treatments with oral antidiabetic agents and insulin.
- Trial name
- NCT01394341
- Testing
- Liraglutide
- Where
- 3 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Bo Feldt-Rasmussen
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Childhood Obesity, Treatment Adherence
The Evira Study: Additional Support During Obesity Treatment
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity.
- Trial name
- NCT06836284
- Testing
- Digi-physical treatment tool, Evira, Obesity medication with liraglutide or semaglutide
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes…
- Trial name
- DUAL™ III (NCT01676116)
- Testing
- insulin degludec/liraglutide, liraglutide, exenatide
- Where
- 109 sites in United States, Australia and 3 more
- Volunteers
- 438 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2, Metabolic Syndrome
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
The most important cause of mortality amongst DM2 patients is cardiovascular disease. An early finding of cardiovascular disease in DM2 and obesity is diastolic dysfunction.
- Conditions
- Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction
- Trial name
- MAGNA VICTORIA (NCT01761318)
- Testing
- Liraglutide
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Leiden University Medical Center
Obesity, Type 2 Diabetes Mellitus
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
The purpose of this study is to access liraglutide influence brown adipose tissue recruitment and its thermogenic effect through hypothalamic activation in obese individuals.
- Trial name
- i-LAB (NCT02718950)
- Testing
- Liraglutide 3.0 mg
- Volunteers
- 20 people
- Sponsor
- University of Campinas, Brazil
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi